Cas:60563-36-2 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one manufacturer & supplier

Chemical Name:5,6-dichloro-3-ethyl-1H-benzimidazol-2-one

CAS.NO:60563-36-2

Synonyms:5,6-Dichloro-1-ethyl-1,3-dihydro-2H-benzimidazole-2-one;5,6-dichloro-1-ethyl-1,3-dihydro-benzoimidazol-2-one;DC-EBIO;5,6-dichloro-3-ethyl benzimidazolone;5,6-Dichlor-1-ethyl-benzimidazolon;5,6-Dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one;5,6-dichloro-1-ethyl-benzimidazolinone;Tocris-1422;5,6-Dichlor-2-oxo-1-ethyl-benzimidazolin;dichloro-EBIO

Molecular Formula:C₉H₈Cl₂N₂O

Molecular Weight:231.08

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.413g/cm3

Index of Refraction:1.592

PSA:37.79000

Exact Mass:230.00100

LogP:2.65630

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 5,6-Dichloro-1-ethyl-1,3-dihydro-2H-benzimidazole-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,dichloro-EBIO physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tocris-1422 Use and application,5,6-dichloro-1-ethyl-1,3-dihydro-benzoimidazol-2-one technical grade,usp/ep/jp grade.

Related News: The rest of South Korea will also consider stopping issuing tourist visas to Chinese nationals, said Park Neung-hoo, the government��s minister of health and welfare. All travelers from China will be separated from the other arrivals for heightened screening at airports. 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one manufacturer The rest of South Korea will also consider stopping issuing tourist visas to Chinese nationals, said Park Neung-hoo, the government��s minister of health and welfare. All travelers from China will be separated from the other arrivals for heightened screening at airports. 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one supplier Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.